BMY Bristol Myers Squibb Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
20:22
Jul 20
Jul 20
AI healthcare efficiency lifts BMY, NVDA
Bristol Myers Squibb purchasing Nvidia's AI computing system illustrates the growing adoption of AI in healthcare, which improves efficiency and speeds drug development. More healthcare companies are expected to follow, making this a powerful theme for both Bristol Myers and Nvidia.
MED
15:10
Jul 20
Jul 20
Bristol Myers Squibb expands its partnership with Nvidia to boost computing power for an AI factory used to create new medicines more quickly.
13:43
Jun 30
Jun 30
US House committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their drug trials in China.
13:43
Jun 30
Jun 30
US House Committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their China drug trials.
13:11
Jun 17
Jun 17
Bristol Myers Squibb Canada announces approval of Breyanzi CAR T cell therapy monitoring and activity updates in Canada.
03:47
Jun 17
Jun 17
The author notes that most large pharma companies have seen minimal M&A activity over the last 24 months while Eli Lilly remains aggressive, providing a factual observation rather than a trade call.
LOW
03:40
Jun 17
Jun 17
The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.
LOW
01:44
Jun 13
Jun 13
The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.
LOW
12:35
Jun 02
Jun 02
Bristol-Myers Squibb reports that its drug Izalontamab Brengitecan shows significant overall survival and progression-free survival improvements in TNBC and ESCC.
18:33
May 15
May 15
SEC FOIA logs reveal ongoing investigations for listed companies, indicating regulatory scrutiny but no directional view expressed.
HIGH
00:39
May 13
May 13
Bristol-Myers Squibb and China's Hengrui Pharma announced a partnership, but the tweet reports the deal without expressing a forward-looking opinion on the stock.
HIGH
04:56
Apr 03
Apr 03
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
17:30
Mar 27
Mar 27
BMY faces the steepest patent cliff with 47% of its revenue at risk and carries a high debt load from aggressive M&A. Despite a cheap valuation, the combination of massive revenue exposure and high debt restricts their flexibility, making them a high-risk investment. Avoid BMY as it is currently a "value trap." Recent M&A acquisitions could yield blockbuster results faster than anticipated, offsetting the cliff.
HIGH
23:48
Mar 25
Mar 25
Cramer agreed with Bob Lang's analysis that it's time to buy big pharma names like Pfizer, Merck, and Bristol Myers for their dividends and safety in a potential slowdown. These companies have strong dividend yields (e.g., Pfizer 6.3%, Merck nearly 3%, Bristol Myers 4.3%), bullish technical indicators (money flow, cup-and-handle patterns), and are recession-resistant as medication demand is inelastic. LONG because they offer yield protection and potential capital appreciation in a potential economic slowdown, making them defensive plays. If the economy avoids a slowdown, these stocks might underperform growth sectors; drug pipeline setbacks could impact earnings.
12:13
Jan 22
Jan 22
Speaker notes BMY's continued commitment to T-cell engager development; no directional view stated.
LOW
About BMY Analyst Coverage
Buzzberg tracks BMY (Bristol Myers Squibb) across 9 sources. 3 bullish vs 0 bearish calls from 10 analysts. Sentiment: predominantly bullish (20%). 15 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: Shannon, Bloomberg, FirstSquawk.